Trump Proposes 15% Global Tariff as Eli Lilly Outperforms Novo Nordisk

Former President Donald Trump has escalated his trade policy rhetoric by proposing a 15% global tariff on imports. This move signals a potential shift toward more aggressive protectionism, raising concerns about global trade volatility and inflationary pressures. Meanwhile, in the pharmaceutical sector, Eli Lilly continues to solidify its leadership in the lucrative obesity drug market. Recent data suggests Eli Lilly is gaining a competitive edge over its primary rival, Novo Nordisk, as market demand for weight-loss treatments surges. Investors are closely monitoring these developments, as the tariff news weighs on broad market indices like the SPY, while Eli Lilly provides a bullish catalyst for the healthcare sector. The combination of macro geopolitical risks and sector-specific growth highlights a complex landscape for global markets.